Dear Colleagues,

After three years of very successful virtual Annual Meetings, we are thrilled to meet in person in 2024 in Bethesda. The ASENT2024 Annual Meeting will highlight the latest therapeutic advances in a broad range neurologic disease states, processes and delivery methods, including nine scientific symposia, a scientific debate, and a Covid update. A few highlights include:

On Thursday, March 14, 2024, the plenary session “Pre-clinical to First in Human in Drug Development” will feature Nathan Fountain, M.D., Thomas E. Worrell, Jr, Professor of Neurology and Epileptology at University of Virginia and Jim Doherty, Ph.D., of Sage Therapeutics to compare the similarities and differences in the preclinical process and infrastructure when developing a neurotherapeutic. As ASENT President, I will personally moderate this fireside chat style discussion.

The two additional unopposed plenary sessions will take place: “Fluid Biomarkers as Endpoints for Neurodegenerative Diseases” on Tuesday, March 12, 2024, and “Parkinson’s Disease Biological Staging and Implications for Therapeutic Trials” on Wednesday, March 13, 2024. Other unopposed sessions include “NIH Update on COVID and CNS disease” with speaker Avindra Nath, M.D., Senior Investigator, NINDS, and a Beta Amyloid Debate will be held Wednesday, March 13, 2024.

Attendees will also have an opportunity to hear top abstracts selected for presentation by the Abstract Review Committee. On Wednesday, March 13, 2024, as many as 20 selected abstracts will be presented as part of the ASENT Pipeline Datablitz. Abstracts qualify for an ASENT Pipeline Data Blitz presentation when they are submitted as an Abstract Submission. Abstracts can be submitted via https://asent.org/AnnualMeeting2024

Other special events include the Careers in Neuroscience Dinner, during which invited speakers showcase the wide range of career opportunities available in neuroscience related fields. Each presenter will take a few minutes to share an overview of their career and highlight any unique career opportunities they have discovered along the way. Participants and faculty from the Training in Neurotherapeutics Discovery and Development for Academic Scientists course also participate in this dynamic event. This reception and dinner are a wonderful way to kick off the meeting on Tuesday, March 12, 2024.

We are excited that the inaugural ASENT Training in Clinical Trials course will be held on Monday, March 12 - Tuesday, March 13, 2024, co-located with the Annual Meeting. Developed by ASENT leadership and led by outstanding faculty, this 1 ½ day course will introduce researchers and clinicians to the principles of neurotherapeutic clinical trial development and implementation.

Finally, ASENT continues its dedication to our international colleagues. We are pleased to welcome guests from the Japanese Society of Neurological Therapeutics and are honored to continue the tradition of neurological education and research among academic neurologists around the world. I, along with the Board of Directors and the Program Committee, invite you to make the most of this outstanding meeting.

Best,
Andrew J. Cole, M.D., F.R.C.P.(C.)
Professor of Neurology
Harvard Medical School
Director, MGH Epilepsy Service
Chief, Division of Clinical Neurophysiology
Vice-Chair for External Affairs,
Dept. of Neurology
President, ASENT
**WHY ATTEND ASENT2024**

ASENT2024 is the premier neurotherapeutics conference where senior leaders through junior faculty and trainees from across payers, providers, employers, investors, fast-growing startups, industry, academia, policymakers, funders and innovation centers gather to ask one question: how can we improve the process of the development and discovery of neurotherapeutics?

Attendees are often surprised to find that more than 50% of participants are practicing physicians and the caliber of speakers is outstanding for a conference that provides ample opportunity to connect, network and converse. Additionally the scientific content showcases the leading edge in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy, the latest drug therapies and devices. The event features plenary sessions, fireside chats, panel discussions, business roundtables, and networking meetings.

**MEETING DETAILS**

- **ASENT2024 Meeting Dates**
  Tues, March 12 - Thurs, March 14, 2024

- **Abstract Submissions Deadline**
  January 22, 2024
  [asent.org/annualmeeting2024](asent.org/annualmeeting2024)

- **Early Registration Bird Deadline**
  December 31, 2023
  [asent.org/annualmeeting2024](asent.org/annualmeeting2024)

- **Hotel Reservation Deadline**
  February 10, 2024
  [asent.org/annualmeeting2024](asent.org/annualmeeting2024)

**WHO ATTENDS**

- Clinician-Investigators
- Neuroscience Trainees
- Neuroscientist Researchers
- Industry Research Scientists
- Clinicians
- Advocacy Group Leaders
- Chairs of Neurology
- Chief Medical Officers
- Chief Scientific Officers
- CEOs
- Founders
- Investors
- Payers
- Innovation Centers
- CROs
- Journal Editors
- Health Journalists
- Drug and Device Companies
- Communication Companies
- Health Systems
- FDA
- NIH
- All ARE WELCOME!
- 50% ARE PREScribers
- 50% ARE PREScribers
CONFERENCE INFORMATION AT A GLANCE

CONFERENCE DATES
March 12 - 14, 2024

LOCATION
Hyatt Regency Bethesda
Bethesda, MD

PROGRAM
Registered sponsors are encouraged to attend all conference sessions, meals, receptions & events.

REGISTRATION
Registration is open & is complimentary in most sponsorship packages.

HOUSING
Discounted housing is available at the Hyatt Regency Bethesda. Rates begin at $219. Housing can be booked here: asent.org/annualmeeting2024

ABSTRACT SUBMISSION DATES
Opens: October 1, 2023
Closes: January 22, 2023
Submit your abstract here: asent.org/annualmeeting2024

PIPELINE SUBMISSION DATES
Opens: October 1, 2023
Closes: January 22, 2024
Submit your abstract here: asent.org/annualmeeting2024

OTHER ACTIVITIES
On March 11-12, The inaugural ASENT Clinical Trials Course will take place onsite. The Neurotherapeutics Drug Discovery and Development Course will run onsite March 12-15 as well.
# REGISTRATION RATES

**Early Bird Discount:** Discounted Rates if purchased before December 31, 2023

## MEMBER RATES

<table>
<thead>
<tr>
<th>Membership Type</th>
<th>Early Bird - (Now - Dec 31)</th>
<th>Standard - (Jan 1 - Mar 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAN Member</td>
<td>$150</td>
<td>$250</td>
</tr>
<tr>
<td>Academic Member</td>
<td>$175</td>
<td>$275</td>
</tr>
<tr>
<td>Advocacy Member</td>
<td>$75</td>
<td>$175</td>
</tr>
<tr>
<td>Clinician Member</td>
<td>$175</td>
<td>$275</td>
</tr>
<tr>
<td>Government Member</td>
<td>$175</td>
<td>$275</td>
</tr>
<tr>
<td>Industry Member</td>
<td>$325</td>
<td>$425</td>
</tr>
<tr>
<td>JSNT Member</td>
<td>$100</td>
<td>$200</td>
</tr>
<tr>
<td>LMIC Member</td>
<td>$50</td>
<td>$150</td>
</tr>
<tr>
<td>Retired Member</td>
<td>$150</td>
<td>$250</td>
</tr>
<tr>
<td>Trainee Member</td>
<td>$75</td>
<td>$175</td>
</tr>
</tbody>
</table>

## NONMEMBER RATES

<table>
<thead>
<tr>
<th>Membership Type</th>
<th>Early Bird - (Now - Dec 31)</th>
<th>Standard - (Jan 1 - Mar 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAN NonMember</td>
<td>$275</td>
<td>$375</td>
</tr>
<tr>
<td>Academic NonMember</td>
<td>$375</td>
<td>$475</td>
</tr>
<tr>
<td>Advocacy NonMember</td>
<td>$150</td>
<td>$250</td>
</tr>
<tr>
<td>Clinician NonMember</td>
<td>$375</td>
<td>$475</td>
</tr>
<tr>
<td>Government NonMember</td>
<td>$225</td>
<td>$325</td>
</tr>
<tr>
<td>Industry NonMember</td>
<td>$575</td>
<td>$675</td>
</tr>
<tr>
<td>JSNT NonMember</td>
<td>$175</td>
<td>$275</td>
</tr>
<tr>
<td>LMIC NonMember</td>
<td>$100</td>
<td>$200</td>
</tr>
<tr>
<td>Retired NonMember</td>
<td>$275</td>
<td>$375</td>
</tr>
<tr>
<td>Trainee NonMember</td>
<td>$150</td>
<td>$250</td>
</tr>
</tbody>
</table>

Register at [asent.org/annualmeeting2024](http://asent.org/annualmeeting2024)
### TUESDAY, MARCH 12, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 8:00am</td>
<td>Registration</td>
</tr>
<tr>
<td>7:00am - 8:00am</td>
<td>Breakfast</td>
</tr>
<tr>
<td>8:00am - 8:30 am</td>
<td>Presidential Welcome Remarks</td>
</tr>
<tr>
<td>8:30am - 10:30am</td>
<td>Symposium: Fluid Biomarkers as endpoints for neurodegenerative diseases</td>
</tr>
<tr>
<td>10:00am - 10:30am</td>
<td>Networking Break</td>
</tr>
<tr>
<td>10:30am - 12:00pm</td>
<td>Symposium: Platform Clinical Trials in Neurology</td>
</tr>
</tbody>
</table>

**Symposium: Fluid Biomarkers as endpoints for neurodegenerative diseases**

This symposium is offered in partnership with the Japanese Society of Neurological Therapeutics. We are honored to have a long partnership with JSNT and pleased to present their delegate.

**DESCRIPTION:** Fluid Biomarkers are being utilized to study neurodegenerative diseases, including Alzheimers and Parkinsons Disease.

**CHAIR:** Larry Altstiel, Promis Neurosciences  
**COCHAIR:** Gail Farfel, Promis Neurosciences  
**FACULTY:**  
- Henrik Zetterberg, University of Gothenburg (Sweden)  
- Suzanne Hendriks, Pentara  
- Dr. Ayami Okuzumi, Juntendo University School of Medicine, JSNT Presenter

**Symposium: Platform Clinical Trials in Neurology**

**DESCRIPTION:** The session will focus on how neurodegenerative disorders can benefit from platform designs using The HEALEY ALS Platform Trial as an example to showcase how the collaborative effort and enrollment in the trial can benefit neurotherapeutics trials.

**CHAIR:** Merit Cudkowicz, MD, MSc, Harvard Medical School/MGH  
**COCHAIR:** Amir Tamiz, PhD, NINDS  
**FACULTY:**  
- Merit Cudkowicz, Harvard Medical School/MGH  
- Melanie Quintana, Berry Consultants  
- Olivier Collington, GlaxoSmithKline  
- Clinton Wright, NINDS
**TUESDAY, MARCH 12, 2024**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00pm - 1:30pm</td>
<td><strong>Special Interest Group Lunches</strong></td>
</tr>
<tr>
<td>1:30pm - 3:00pm</td>
<td><strong>CONCURRENT Symposium:</strong> Exosome in Neurotherapeutics</td>
</tr>
<tr>
<td></td>
<td>DESCRIPTION: Extracellular vesicles (EVs) have wide-ranging implications in numerous disease areas. Targeting these EVs as a therapeutic strategy is an ever increasing field. During this symposium speakers will look at EV biomarkers, EVs as therapeutics, and EVs for the clinical and preclinical diagnosis of Alzheimer’s disease and other neurological and psychiatric diseases.</td>
</tr>
<tr>
<td></td>
<td>CHAIR: Dimitrios Kapogiannis, MD, National Institute on Aging</td>
</tr>
<tr>
<td></td>
<td>COCHAIR: Carolyn Tallon, PhD, ALTPEP</td>
</tr>
<tr>
<td></td>
<td>FACULTY:</td>
</tr>
<tr>
<td></td>
<td>Dimitrios Kapogiannis, MD, National Institute on Aging</td>
</tr>
<tr>
<td></td>
<td>Carlos Nogueras-Ortiz, PhD, National Institute on Aging</td>
</tr>
<tr>
<td></td>
<td>TBD PhD, Johns Hopkins Drug Discovery</td>
</tr>
<tr>
<td>1:30pm - 3:00pm</td>
<td><strong>CONCURRENT Symposium:</strong> Digital Biomarkers in CNS clinical studies</td>
</tr>
<tr>
<td></td>
<td>DESCRIPTION: The field of neuroscience is rapidly advancing with groundbreaking technologies and methodologies. In recent years, the emergence of digital biomarkers has revolutionized clinical studies in Central Nervous System disorders. This session will delve into the promising role of digital biomarkers in CNS clinical studies, exploring their potential to enhance diagnosis, monitoring, and treatment evaluation. During this session, esteemed experts in the field will present their latest research and share insights on the application of digital biomarkers across a range of CNS disorders. Attendees will gain a comprehensive understanding of the opportunities and challenges associated with leveraging digital biomarkers in clinical research.</td>
</tr>
<tr>
<td></td>
<td>CHAIR: Bibi Bielokova</td>
</tr>
<tr>
<td></td>
<td>COCHAIR: Sharon Tamir</td>
</tr>
<tr>
<td></td>
<td>FACULTY:</td>
</tr>
<tr>
<td></td>
<td>James Berry (nQ)</td>
</tr>
<tr>
<td></td>
<td>Rivka Kreitman / Vivian DeWoskin from NeuraLight</td>
</tr>
<tr>
<td></td>
<td>Dr. Ashkan Vaziri, Ph.D., Founder and CEO, BioSensics LLC</td>
</tr>
<tr>
<td>3:00pm - 3:15pm</td>
<td>Networking Break</td>
</tr>
<tr>
<td>3:15pm - 5:00pm</td>
<td><strong>CONCURRENT Symposium:</strong> Opportunities to streamline development of gene therapies for rare diseases</td>
</tr>
<tr>
<td></td>
<td>DESCRIPTION: A significant percentage of rare diseases affecting 30 million people in the US alone are neurological, and 90% of rare childhood disorders have major neurological effects. Many rare diseases stem from single-gene variations, they may be addressable using rapidly maturing genetic technologies, such as antisense oligonucleotides, small interfering RNAs, gene therapy and gene editing. Recent advances in gene therapies have encouraged the scientific community to pursue these treatments as disease modifying treatments that potentially bring significant benefit to the patients. This symposium will address end-to-end regulatory path for individualized gene therapies</td>
</tr>
<tr>
<td></td>
<td>CHAIR: Gopa Raychaudhuri, PhD, Associate Director for Special Programs, FDA/CBER</td>
</tr>
<tr>
<td></td>
<td>COCHAIR: Amir Tamiz, PhD, NINDS</td>
</tr>
<tr>
<td></td>
<td>FACULTY:</td>
</tr>
<tr>
<td></td>
<td>Lawrence Stark, PhD, Novartis</td>
</tr>
<tr>
<td></td>
<td>Steven Gray, MD, UT Southwestern</td>
</tr>
<tr>
<td></td>
<td>Philip J. Brooks, PhD, NIH/NCATS</td>
</tr>
</tbody>
</table>
### TUESDAY, MARCH 12, 2024

**3:15pm - 5:00pm**

**CONCURRENT Symposium: Current Research and Advances in Multiple Sclerosis**

**DESCRIPTION:** Microbial agents including viruses have long been incriminated as triggers in multiple sclerosis (MS). There is mounting evidence that EBV might play a role in MS pathogenesis. Stem cells transplantation therapy for MS is currently being evaluated in clinical trials including mesenchymal stem cell and autologus stem cells. The symposium will address advances in these three aspects of MS.

CHAIR: Suhayl Dhib-Jalbut, MD, Rutgers School of Medicine  
COCHAIR: Steve Jacobson, PhD, NIH

FACULTY:  
Maria Inés Gaitán, MD, NIH  
Steve Jacobson, PhD, NINDS  
Marjan Gharagozloo, Ph.D., Johns Hopkins

**5:00pm - 6:00pm**

Cocktail Reception

**6:00pm - 8:00pm**

**ASENT Careers Dinner**  
Each year ASENT invites a selection of speakers to informally share the trajectory of their career. We ask our speakers to come with no slides and a willingness to answer questions as there are many early career attendees in the audience.

Speakers to be announced

### WEDNESDAY, MARCH 13, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 8:00am</td>
<td>Foyer Ballroom Level</td>
<td>Registration</td>
</tr>
<tr>
<td>7:00am - 8:00am</td>
<td>Foyer Ballroom Level</td>
<td>Breakfast</td>
</tr>
<tr>
<td>8:00am - 8:30 am</td>
<td>Regency 1</td>
<td><strong>ASENT Business Meeting</strong></td>
</tr>
</tbody>
</table>
| 8:30am - 10:00 am | Regency 1       | **Symposium:** Parkinson's disease biological staging and implications for therapeutic trials  
**DESCRIPTION:** Biological staging of Parkinson's disease is being proposed with use of imaging and cerebrospinal fluid biomarkers and prodromal clinical features. There is momentum in the field to define Parkinson's disease according to biological markers rather than traditional clinical features. This session seeks to explore the scientific, clinical, and regulatory issues surrounding pathways for therapeutics development using this framework.  
CHAIR: Ludy Shih, MD, MMSc, FAAN, FANA, Boston University School of Medicine  
COCHAIR: Kathleen Poston, M.D., M.S., Stanford University  
FACULTY  
Kathleen Poston, M.D., M.S., Stanford University  
Kevin Biglan, MD, MPH, Eli Lilly and Company  
Jennifer Goldman, MD, MS, Lewy Body Dementia Association |
| 10:00am - 10:30am | Foyer Ballroom Level | Networking Break                         |
### MEETING OVERVIEW

**WEDNESDAY, MARCH 13, 2024**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30am - 11:00am</td>
<td><strong>SPECIAL UPDATE</strong>: Covid CNS Update</td>
</tr>
<tr>
<td></td>
<td>CHAIR: Debra J. Ehrlich, MD, MS, NINDS</td>
</tr>
<tr>
<td></td>
<td>COCHAIR: Sharon Tamir, Mitsubishi Tanabe Pharma America</td>
</tr>
<tr>
<td></td>
<td>FACULTY: Avindra Nath, MD, NINDS</td>
</tr>
<tr>
<td>11:00am - 11:30am</td>
<td>Pick up Lunch</td>
</tr>
<tr>
<td>11:30am - 1:00</td>
<td><strong>DEBATE</strong>: Beta Amyloid Debate</td>
</tr>
<tr>
<td></td>
<td>CHAIR: Amir Tamiz, PhD, NIH</td>
</tr>
<tr>
<td></td>
<td>COCHAIR: Dietrich Haubenberger, MD, Neurocrine Biosciences</td>
</tr>
<tr>
<td></td>
<td>FACULTY: Madhav Thambisetty, MD, PhD, NIH</td>
</tr>
<tr>
<td></td>
<td>Gil Rabinovici, MD, FAAN, FANA, University of California, San Francisco</td>
</tr>
<tr>
<td>1:00pm - 1:30pm</td>
<td>Networking Break</td>
</tr>
<tr>
<td>1:30pm - 3:00pm</td>
<td><strong>Pipeline Presentations</strong></td>
</tr>
</tbody>
</table>
|                  | Submitted abstracts that most closely conform to the ASENT Abstract criteria, showcase new and emerging data with scientific or clinical impact and align with ASENT goals may also be selected for a 10-minute oral presentation (including 2 minute Q&A) at one of our Pipeline Presentation sessions. ASENT encourages abstracts from private, public and startup companies, foundations and government or academic labs that contain neurotherapeutic research results. Past presenters have reported the following results:  
- increase in stock values in the days following the presentation  
- financially beneficial partnerships as a result of presentation  
- development of new companies as a result of participation in meeting  
To submit an abstract visit: [https://asent.org/AnnualMeeting2024](https://asent.org/AnnualMeeting2024) |
| 3:00pm - 3:30pm  | Networking Break                                                     |
| 3:30pm - 5:00pm  | **Pipeline Presentations**                                            |
|                  | Submitted abstracts that most closely conform to the ASENT Abstract criteria, showcase new and emerging data with scientific or clinical impact and align with ASENT goals may also be selected for a 10-minute oral presentation (including 2 minute Q&A) at one of our Pipeline Presentation sessions. ASENT encourages abstracts from private, public and startup companies, foundations and government or academic labs that contain neurotherapeutic research results. Past presenters have reported the following results:  
- increase in stock values in the days following the presentation  
- financially beneficial partnerships as a result of presentation  
- development of new companies as a result of participation in meeting  
To submit an abstract visit: [https://asent.org/AnnualMeeting2024](https://asent.org/AnnualMeeting2024) |
| 5:00pm - 6:00pm  | Cocktail and Poster Reception                                         |
| 6:00pm - 8:00pm  | Neurotherapeutics Dinner  
  Guest Speaker: Irfan Qureshi, M.D., CMO, Biohaven                  |
|                  | This dinner symposium is a combined effort of the Training in Neurotherapeutics Discovery and Development Course and the ASENT2024 Annual Meeting. All participants are welcome to attend.  
  CHAIR: Michael Rogawski, MD, PhD, University of California, Davis  
### THURSDAY, MARCH 14, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 8:00am</td>
<td>Registration and Breakfast</td>
</tr>
<tr>
<td>8:00am - 8:30am</td>
<td>Presidential Closing Day Remarks</td>
</tr>
</tbody>
</table>
| 8:30am - 10:00am | **Presidential Symposium:** Pre-clinical to First in Human In Drug Development  
DESCRIPTION: This fireside chat will feature speakers from both a small independent academic startup as well as a speaker from a large pharmaceutical company to compare and contrast the similarities and differences in the preclinical process and infrastructure when developing a neurotherapeutic. This discussion will be moderated by ASENT President Andrew Cole, MD.  
CHAIR: Nathan Fountain, MD, University of VA School of Medicine  
FACULTY:  
Nathan Fountain, MD, University of Virginia  
Jim Doherty, PhD, Sage Therapeutics |
| 10:00am - 10:30am| Networking Break                                                       |
| 10:30am - 12:00 pm| **Symposium:** Animal Models in Neurotherapeutics: the good, the bad and the ugly.  
DESCRIPTION: Choice of animal models in evaluating novel solutions in neurodegeneration (and neuroinflammation)  
CHAIR: Carolyn Tallon, PhD, AltPep  
CO-CHAIR: Amy Easton, PhD, Target ALS  
FACULTY:  
Amy Easton, Target ALS  
Stacey J. Sukoff Rizzo, PhD, University of Pittsburgh  
Cameron Metcalf, PhD, University of Utah  
Charles K. Meshu, PhD, Oregon Health and Science University |
| 10:30am - 12:00 pm| **Symposium:** Novel Delivery Systems in CNS  
DESCRIPTION: Oligonucleotides and antibodies are increasingly proposed to provide significant benefit for central nervous system disorders. These modalities offer great promise to change the course of a disease. However, delivery of these therapeutics remains a significant challenge as they don’t readily penetrate the blood brain barrier and therefore, require invasive delivery mechanisms. Fundamental multidisciplinary research in blood-brain barrier biology and protein engineering is ongoing to fully appreciate the great promise of these therapeutic modalities. This symposium will highlight innovative approaches to improve biotherapeutics delivery to the brain.  
CHAIR: Ben Deverman, PhD, MIT and Harvard  
CO-CHAIR: Amir Tamiz, PhD, NINDS  
FACULTY:  
TBD |
|                 | Meeting Concludes                                                     |
PROGRAM COMMITTEE

CHAIRS
Sharon Tamir, Chair
*Mitsubishi Tanabe Pharma America*
Dietrich Haubenberger, MHSc, MD
*Neurocrine*

MEMBERS
C. Anthony Altar, PhD
*Splice Therapeutics*
Deena Andreola
*Takeda*
Enrique Carrazana, MD
*Neurelis*
Suhayl Dhib-Jalbut, MD,
*Rutgers-Robert Wood Johnson Medical School*
Debra Ehrlich, MD, MS
*NINDS*
Gail Farfel, PhD
*ProMIS Neurosciences*

Aditya Joshi, MD
*University of Pennsylvania*
Michelle Manzo, MPH
*UCB*
Ludy Shih, MD, MMSc
*Boston University Medical Campus*
Amir Tamiz, PhD
*NINDS*
Carolyn Tallon, PhD
*AltPep*
Abstract Deadline
January 22, 2024
asent.org/
annualmeeting2024

Early Bird Deadline
December 31, 2023
asent.org/
annualmeeting2024

Hotel Reservation Deadline
February 10, 2024
asent.org/
annualmeeting2024

Register at asent.org/annualmeeting2024